Johnson & Johnson ($JNJ) and Bayer's blockbuster candidate Xarelto just won access to a new market--one that could eventually account for about $600 million in sales. It's just the latest in a series of indications added to the clot fighter's label.
Thank you, Xarelto, Mirena, Cipro and friends. On the strength of these fast-growing products, Bayer's pharma division out-grew its other businesses, with a gain in net sales of 6.1%, to €2.73 billion ($3.545 billion).
You can't accuse Bayer of lacking diversity. Its pharma business has cousins in plastics and agricultural chemicals, just to name two. But CEO Marijn Dekkers wants to broaden his drug unit's horizons, too. Hence the $1.2 billion buyout of U.S. vitamin-and-supplement maker Schiff Nutrition International.
Qiagen has signed on with Bayer to develop companion diagnostics for Bayer's solid tumor treatments, using the company's QIAsymphony Dx platform.
German drug giant Bayer is halting efforts to sell its blood glucose meter business, at least for now, unable to find a buyer willing to meet its asking price, Financial Times Deutschland reports.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
It's the endgame for 2012 election candidates--and for supporters that have shelled out cash to support their bids for votes. As usual, the pharma business is right there in the fray, with political action committees and employees donating hundreds of thousands, if not millions.
United Therapeutics suffered a setback in its pursuit of commercializing an oral therapy for pulmonary arterial hypertension (PAH) yesterday, as the FDA rejected the company's new drug application with a dreaded complete response letter.
Just days after nabbing a speedy FDA approval of its cancer drug Stivarga (regorafenib), Bayer says it nailed positive Phase III data on its new drug for rare cases of pulmonary arterial hypertension.
Bayer and Regeneron ($REGN) are touting new data on their macular degeneration drug Eylea. And no wonder: The VIEW 1 and VIEW 2 studies found that Eylea matched rival drug Lucentis in head-to-head comparisons.